ITM to Share Phase 3 Trial Results of [177Lu]Lu-edotreotide for Grade 1 & 2 GEP-NETs at ENETS Conference

Garching / Munich, February 25 2025 – ITM, a prominent radiopharmaceutical biotech firm, has announced it will present topline data from its Phase 3 COMPETE trial in an oral presentation at the 22^nd Annual European Neuroendocrine Tumor Society (ENETS) Conference 2025, taking place in Kraków, Poland from March 5 – March 7, 2025.

The COMPETE trial assessed [¹⁷⁷Lu]Lu-edotreotide (ITM-11), ITM’s proprietary, synthetic, targeted radiotherapeutic, against everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This follows ITM’s announcement on January 28, 2025, that the trial achieved its primary endpoint.

Oral Presentation Details
Title: Efficacy and safety of [¹⁷⁷Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Date and Time: March 6, 2025; 10:05 am – 10:12 am CET

Session and Room Number: Clinical science, Session 1: Theranostics in NENs – Integrating experience for a brighter future; Auditorium Hall (S1)

Presenter: Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d’Hebron University Hospital, Barcelona

For further information, please contact:

Media Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: 

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is committed to delivering innovative radiopharmaceutical therapeutics and diagnostics for difficult-to-treat tumors. Our goal is to address the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply. With the principle of improved patient benefit guiding all our actions, ITM is advancing a broad precision oncology pipeline, which includes several phase 3 studies. This pipeline combines the company’s high-quality radioisotopes with a variety of targeting molecules. By utilizing our two decades of pioneering radiopharma expertise, central position in the industry, and established global network, ITM aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.

Attachment